Recombinant Human PAI-1
Catalog Number : 140-04
Plasminogen Activator Inhibitor-1 (PAI-1, Serpin E1) is a member of the serpin family of serine protease inhibitors, and is the primary inhibitor of urokinase and tissue plasminogen activator (tPA). PAI-1 is expressed predominantly in adipose, liver and vascular tissues, and is also produced by certain tumor cells. Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity related factors such as TNFα, glucose, insulin, and very-low-density lipoprotein. The obesity related elevation of PAI-1 levels along with the consequential deficiency in plasminogen activators can lead directly to increased risk of thrombosis and other coronary diseases. Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease. PAI-1 can also specifically bind vitronectin (VTN) to form a stable active complex with an increased circulatory half life relative to free PAI-1. Recombinant human PAI-1 is a 42.7 kDa protein containing 379 amino acid residues.
Above 95% as determined by SDS-PAGE Analysis.
Determined by its inhibitory effect against single chain tPA induced cleavage of a chromogenic substrate in Imidazole Buffer at 37oC. Half maximal inhibition against 1.0 μg/ml of single chain tPA was obt
VHHPPSYVA HLASDFGVR VFQQVAQAS KDRNVVFSP YGVASVLAM LQLTTGGET QQQIQAAMG FKIDDKGMA PALRHLYKE LMGPWNKDE ISTTDAIFV QRDLKLVQG FMPHFFRLF RSTVKQVDF SEVERARFI INDWVKTHT KGMISNLLG KGAVDQLTR LVLVNALYF NGQWKTPFP DSSTHRRLF HKSDGSTVS VPMMAQTNK FNYTEFTTP DGHYYDILE LPYHGDTLS MFIAAPYEK EVPLSALTN ILSAQLISH WKGNMTRLP RLLVLPKFS LETEVDLRK PLENLGMTD MFRQFQADF TSLSDQEPL HVAQALQKV KIEVNESGT VASSSTAVI VSARMAPEE IIMDRPFLF VVRHNPTGT VLFMGQVME P
|Research Interest:||Cancer, Angiogenesis, Metabolic Regulation and Diabetes|
|Protein Cross Reactivity:||NULL|